Evidence map›Paper›PMID 30003082›Full record

ReviewFrontiers in cell and developmental biology2018

Roles of PLODs in Collagen Synthesis and Cancer Progression.

Yifei Qi, Ren Xu

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers.

0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

141 citing papers in PubMed.

  1. Prospective exploratory pilot study of 18 F-FMISO PET/CT for assessing tumor hypoxia in soft tissue sarcomas.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Trial
  2. Article
  3. Article
  4. LiposomalInternational journal of molecular sciences · 2026
    Article
  5. Metabolic-epigenetic reprogrammingActa pharmaceutica Sinica. B · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Genome-Wide Analysis of Copy Number Variation in Vietnamese Local Chickens.Animals : an open access journal from MDPI · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

81 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yifei QiMarkey Cancer Center, University of Kentucky, Lexington, KY, United States.
Ren XuMarkey Cancer Center, University of Kentucky, Lexington, KY, United States.

Funding

Roles of Hsp47 in Breast Cancer ProgressionR01CA207772 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI XU, REN · 2017 to 2025
$3.1M
Roles of RORalpha in breast cancer development and progressionR01CA215095 · NCI · UNIVERSITY OF KENTUCKY · PI XU, REN · 2017 to 2022
$1.7M
Systemic delivery of miR-29 for basal-like breast cancer treatmentR21CA209045 · NCI · UNIVERSITY OF KENTUCKY · PI SHU, DAN, XU, REN · 2016 to 2017
$375k
NCI NIH HHS R01 CA207772NCI NIH HHS R01 CA215095NCI NIH HHS R21 CA209045
6 · The paper itself

Abstract

Collagen is the major component of extracellular matrix. Collagen cross-link and deposition depend on lysyl hydroxylation, which is catalyzed by procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD). Aberrant lysyl hydroxylation and collagen cross-link contributes to the progression of many collagen-related diseases, such as fibrosis and cancer. Three lysyl hydroxylases (LH1, LH2, and LH3) are identified, encoded by

Indexed as

cancer progressioncollagenextracellular matrixlysyl hydroxylationprocollagen-lysine 2-oxoglutarate 5-dioxygenase

Identifiers

PMID30003082
PMCPMC6031748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.